Targeting drug-metabolizing enzymes for effective chemoprevention and chemotherapy

Drug Metabolism and Disposition

Volumn 38, Issue 4, 2010, Pages 539-544

  Swanson, Hollie I ^a   Njar, Vincent C O ^b   Yu, Zhen ^c   Castro, David J ^c   Gonzalez, Frank J ^d   Williams, David E ^c   Huang, Ying ^e   Kong, Ah Ng T ^e   Doloff, Joshua C ^f   Ma, Jie ^f   Waxman, David J ^f   Scott, Emily E ^g  

^a UNIVERSITY OF KENTUCKY   (United States)

^b THOMAS JEFFERSON UNIVERSITY   (United States)

^c OREGON STATE UNIVERSITY   (United States)

^d NATIONAL CANCER INSTITUTE   (United States)

^e RUTGERS UNIVERSITY   (United States)

^f Boston University   (United States)

^g UNIVERSITY OF KANSAS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

13BETA HYDROXY 17 (1H BENZIMIDAZOLE 1 YL)ANDROSTA 5,16 DIENE; 3 INDOLEMETHANOL; ABIRATERONE; ANTINEOPLASTIC AGENT; AROMATASE; AXITINIB; BICALUTAMIDE; CHLOROPHYLL; CURCUMIN; CYCLOOXYGENASE 2; CYCLOPHOSPHAMIDE; CYTOCHROME P450; CYTOCHROME P450 17; CYTOCHROME P450 1B1; DRUG METABOLIZING ENZYME; EPIGALLOCATECHIN GALLATE; INDUCIBLE NITRIC OXIDE SYNTHASE; INTERLEUKIN 1BETA; INTERLEUKIN 6; KETOCONAZOLE; NEMORUBICIN; ONYX 015; SULFORAPHANE; TELOMERASE REVERSE TRANSCRIPTASE; TOK 001; TRANSCRIPTION FACTOR NRF2; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; BREAST CANCER; CANCER INHIBITION; CARCINOGENESIS; CHEMOPROPHYLAXIS; CLINICAL TRIAL; CONFERENCE PAPER; DRUG ANTAGONISM; DRUG EFFECT; DRUG EFFICACY; DRUG INHIBITION; DRUG METABOLISM; GLIOSARCOMA; HUMAN; NONHUMAN; PHYTOCHEMISTRY; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION; T CELL LYMPHOMA; TEA; TUMOR GROWTH;

ANGIOGENESIS INHIBITORS; ANIMALS; ANTINEOPLASTIC AGENTS; ARYL HYDROCARBON HYDROXYLASES; CARCINOGENS; CYTOCHROME P-450 ENZYME SYSTEM; ENDOTHELIAL CELLS; ENZYMES; FEMALE; HUMANS; MALE; MICE; NEOPLASMS; NF-E2-RELATED FACTOR 2; PHARMACEUTICAL PREPARATIONS; POLYCYCLIC HYDROCARBONS, AROMATIC; PREGNANCY; PRODRUGS; PROSTATIC NEOPLASMS; STEROID 17-ALPHA-HYDROXYLASE;

EID: 77950284080     PISSN: 00909556     EISSN: 1521009X     Source Type: Journal    
DOI: 10.1124/dmd.109.031351     Document Type: Conference Paper

References (24)

1. Attard G, Reid AH, Olmos D, and de Bono JS (2009a) Antitumor activity with CYP17 blockade indicates that castration-resistant prostate cancer frequently remains hormone driven. Cancer Res 69:4937-4940.
2. Attard G, Swennenhuis JF, Olmos D, Reid AH, Vickers E, A'Hern R, Levink R, Coumans F, Moreira J, Riisnaes R, et al. (2009b) Characterization of ERG, AR and PTEN gene status in circulating tumor cells from patients with castration-resistant prostate cancer. Cancer Res 69:2912-2918.
3. Bruno RD, Gover TD, Burger AM, Brodie AM, and Njar VC (2008) 17alpha-Hydroxylase/17,20 lyase inhibitor VN/124-1 inhibits growth of androgen-independent prostate cancer cells via induction of the endoplasmic reticulum stress response. Mol Cancer Ther 7:2828-2836.
4. Bruno RD and Njar VC (2007) Targeting cytochrome P450 enzymes: a new approach in anti-cancer drug development. Bioorg Med Chem 15:5047-5060.
5. Castro DJ, Baird WM, Pereira CB, Giovanini J, Lohr CV, Fischer KA, Yu Z, Gonzalez FJ, Krueger SK, and Williams DE (2008) Fetal mouse Cyp1b1 and transplacental carcinogenesis from maternal exposure to dibenzo(a,l)pyrene. Cancer Prev Res (Phila Pa) 1:128-134.
6. Chen CS, Jounaidi Y, Su T, and Waxman DJ (2007) Enhancement of intratumoral cyclophosphamide pharmacokinetics and antitumor activity in a P450 2B11-based cancer gene therapy model. Cancer Gene Ther 14:935-944.
7. De Flora S and Ferguson LR (2005) Overview of mechanisms of cancer chemopreventive agents. Mutat Res 591:8-15.
8. Doloff JC, Waxman DJ, and Jounaidi Y (2008) Human telomerase reverse transcriptase promoter-driven oncolytic adenovirus with E1B-19 kDa and E1B-55 kDa gene deletions. Hum Gene Ther 19:1383-1400.
9. Handratta VD, Vasaitis TS, Njar VC, Gediya LK, Kataria R, Chopra P, Newman D Jr, Farquhar R, Guo Z, Qiu Y, et al. (2005) Novel C-17-heteroaryl steroidal CYP17 inhibitors/ antiandrogens: synthesis, in vitro biological activity, pharmacokinetics, and antitumor activity in the LAPC4 human prostate cancer xenograft model. J Med Chem 48:2972-2984.
10. Harris WP, Mostaghel EA, Nelson PS, and Montgomery B (2009) Androgen deprivation therapy: progress in understanding mechanisms of resistance and optimizing androgen depletion. Nat Clin Pract Urol 6:76-85.
11. Jordan VC and Brodie AM (2007) Development and evolution of therapies targeted to the estrogen receptor for the treatment and prevention of breast cancer. Steroids 72:7-25.
12. Khor TO, Huang MT, Kwon KH, Chan JY, Reddy BS, and Kong AN (2006) Nrf2-deficient mice have an increased susceptibility to dextran sulfate sodium-induced colitis. Cancer Res 66: 11580-11584.
13. Lu H, Chen CS, and Waxman DJ (2009) Potentiation of methoxymorpholinyl doxorubicin antitumor activity by P450 3A4 gene transfer. Cancer Gene Ther 16:393-404.
14. Ma J and Waxman DJ (2008) Modulation of the antitumor activity of metronomic cyclophosphamide by the angiogenesis inhibitor axitinib. Mol Cancer Ther 7:79-89.
15. Moreira VM, Salvador JA, Vasaitis TS, and Njar VC (2008) CYP17 inhibitors for prostate cancer treatment-an update. Curr Med Chem 15:868-899.
16. Nebert DW and Dalton TP (2006) The role of cytochrome P450 enzymes in endogenous signalling pathways and environmental carcinogenesis. Nat Rev Cancer 6:947-960.
17. Prawan A, Saw CL, Khor TO, Keum YS, Yu S, Hu L, and Kong AN (2009) Anti-NF-kappaB and anti-inflammatory activities of synthetic isothiocyanates: effect of chemical structures and cellular signaling. Chem Biol Interact 179:202-211.
18. Russo GL (2007) Ins and outs of dietary phytochemicals in cancer chemoprevention. Biochem Pharmacol 74:533-544.
19. Small EJ, Baron AD, Fippin L, and Apodaca D (1997) Ketoconazole retains activity in advanced prostate cancer patients with progression despite flutamide withdrawal. J Urol 157:1204-1207.
20. Sporn MB, Dunlop NM, Newton DL, and Smith JM (1976) Prevention of chemical carcinogenesis by vitamin A and its synthetic analogs (retinoids). Fed Proc 35:1332-1338.
21. Vasaitis T, Belosay A, Schayowitz A, Khandelwal A, Chopra P, Gediya LK, Guo Z, Fang HB, Njar VC, and Brodie AM (2008) Androgen receptor inactivation contributes to antitumor efficacy of 17{alpha}-hydroxylase/17,20-lyase inhibitor 3beta-hydroxy-17-(1H-benzimidazole-1-yl)androsta-5,16-diene in prostate cancer. Mol Cancer Ther 7:2348-2357.
22. Wattenberg LW (1985) Chemoprevention of cancer. Cancer Res 45:1-8.
23. Yu Z, Loehr CV, Fischer KA, Louderback MA, Krueger SK, Dashwood RH, Kerkvliet NI, Pereira CB, Jennings-Gee JE, Dance ST, et al. (2006a) In utero exposure of mice to dibenzo[a,l]pyrene produces lymphoma in the offspring: role of the aryl hydrocarbon receptor. Cancer Res 66:755-762.
24. Yu Z, Mahadevan B, Löhr CV, Fischer KA, Louderback MA, Krueger SK, Pereira CB, Albershardt DJ, Baird WM, Bailey GS, et al. (2006b) Indole-3-carbinol in the maternal diet provides chemoprotection for the fetus against transplacental carcinogenesis by the polycyclic aromatic hydrocarbon dibenzo[a,l]pyrene. Carcinogenesis 27:2116-2123.